NEW HAVEN, Conn.–(BUSINESS WIRE)–Aug. 13, 2026– Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter ended June 30, 2026 and provided business updates.
“The second quarter was highly productive for Yarrow and included the initiation of our Phase 2a/2b clinical trial of YB-101, a potential first-in-class anti-TSHR antibody that represents a highly differentiated approach to treating both Graves’ disease and thyroid eye disease. These two diseases converge on the TSHR, a single receptor that no approved therapy targets directly, giving Yarrow the unique opportunity to treat both conditions with a single molecule,” said Rebecca V. Frey, PharmD, President and Chief Executive Officer of Yarrow. “With the merger with VYNE Therapeutics now complete and cash runway expected to fund operations into 2028, we’re well-positioned to advance YB-101 in GD, where dosing is underway and Phase 2a data are expected in the second half of 2027. Additionally, GenSci continues its Phase 1 MAD study in TED in China, which we expect to inform our global TED development plans.”
Second Quarter 2026 Highlights and Upcoming Milestones
YB-101: potential first-in-class anti-TSHR antibody for GD and TED
- The U.S. Food and Drug Administration (FDA) granted Fast Track Designation for YB-101 in GD.
- The Company initiated the Phase 2a/2b trial of YB-101 in patients with Graves’ disease (GD), with or without concurrent thyroid eye disease (TED).
- The Phase 2a portion of the trial is a randomized, placebo-controlled proof-of-concept trial of 32 patients across four cohorts designed to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy over 24 weeks, including the percentage of patients who are euthyroid and off anti-thyroid drugs, as well as relevant measures of orbitopathy in patients with concurrent TED.
- Topline results from the Phase 2a portion of the trial are expected in the second half of 2027.
- The Phase 2b portion of the trial is expected to commence in the first half of 2028.
- Licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd. (“GenSci”), continues to advance YB-101 (also known as GenSci098) in greater China. Data from GenSci’s ongoing Phase 1 multiple ascending dose (MAD) trial in TED are anticipated in the second half of 2027 and are expected to inform the Company’s global TED development plans.